ArticleJournal of neuro-oncology2025
Long term outcomes following upfront stereotactic body radiotherapy alone for spinal metastases.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stereotactic body radiation therapy in elderly patients with spinal metastases.Journal of neuro-oncology · 2026Article
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Clinical outcomes of stereotactic body radiotherapy for spinal metastases with paraspinal extension.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough stereotactic body radiotherapy (SBRT) has radically transformed the treatment paradigm for spinal metastases, long-term outcomes of upfront SBRT in patients with spinal metastases remain underreported.
methodsA cohort of 100 patients (131 treatments) with spinal metastases treated with upfront SBRT alone from 2001 to 2024 was analyzed. Patients with prior lesion-specific surgery or radiotherapy, or less than 6 months of follow-up, were excluded. The median single- and multi-fraction prescription doses were 16-Gy (IQR: 16-18) and 24-Gy (IQR: 24-27), respectively.
resultsThe median follow-up was 21 months (IQR: 12-57). The 1- and 2-year local tumor control (LTC) rates were 86% (95%CI: 80-92%) and 81% (95%CI: 73-88%), respectively. On multivariable analysis, tumor volume > 23 cc (HR: 3.20, 95%CI: 1.02-10.1, p = 0.047) was significantly associated with worsened LTC. Patient-reported pain improved or remained stable in 89% and 87% of cases at 6- months and 12-months following SBRT. The median overall survival (OS) was 33 months (IQR: 13-57), with polymetastatic disease (HR: 1.80, 95%CI: 1.05-3.09, p = 0.032) being significantly associated with worsened OS. There were 19 (15%) vertebral compression fractures (VCFs) that developed following SBRT. On multivariable analysis, lumbar lesions (HR: 2.61, 95%CI: 1.01-6.76, p = 0.048) and baseline VCFs (HR: 2.80, 95%CI: 1.10-7.09, p = 0.030) were predictive of VCF development following SBRT.
conclusionsUpfront SBRT alone provides durable long-term local tumor control and sustained pain relief, with minimal toxicity. These findings support the integration of SBRT as a definitive, minimally invasive treatment option for appropriately selected patients, which may obviate the need for future open surgical intervention.
Indexed as
Identifiers
40522562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.